Pfizer (PFE.US) and BioNTech (BNTX.US) announced positive results for their flu mRNA vaccine.
1min read Today, Pfizer (PFE.US) and BioNTech (BNTX.US) announced the latest progress of their second-generation three-valent (tIRV) flu mRNA vaccine in a Phase 2 trial, which showed encouraging data with strong immunogenicity against all virus strains compared to the standard flu vaccine.
It is difficult for global health experts to predict the best-matched virus strains for the next flu season as the virus strains are constantly changing, as they are selected more than six months before the target flu season begins. The flexibility of mRNA technology and its ability to manufacture quickly may enable better virus matching in the coming years, and mRNA technology can also achieve rapid and large-scale vaccine production in the case of a pandemic.
Noes of any safety signals for the vaccine have not been reported so far. Detailed Phase 2 trial data for adults aged 65 and above will be published later.
